Physician profile
Donald Hamner
NPI 1275642860
$1,141.74
in general payments reported to CMS, 2019-2025
14 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.80 · 2020: $15.04 · 2021: $160 · 2022: $251 · 2023: $285 · 2024: $245 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $657.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $230.56 | 2021-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $138.98 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $135.33 | 2022-2024 | Repatha, Otezla, Prolia |
| Novartis Pharmaceuticals Corporation | $127.24 | 2023-2024 | |
| Pfizer INC. | $125.56 | 2019-2024 | |
| Abbvie INC. | $95.65 | 2021-2025 | |
| Lilly USA, LLC | $78.62 | 2021-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $65.80 | 2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $43.08 | 2022 | |
| Almatica Pharma LLC | $36.88 | 2022-2023 | Loreev Xr, Gralise |
| Phathom Pharmaceuticals, INC. | $23.12 | 2025 | Voquezna |
| Astellas Pharma US INC | $15.04 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.64 | 2022 | |
| Xeris Pharmaceuticals, INC. | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Hamner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.